Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antiviral compounds inhibitors of HCV NS5B

A compound and selected technology can be applied in the direction of antiviral agents, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as limiting practicability

Active Publication Date: 2015-04-01
GILEAD SCI INC
View PDF8 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although drugs targeting the liver are widely used and have shown effectiveness, toxicity and other side effects limit their usefulness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiviral compounds inhibitors of HCV NS5B
  • Antiviral compounds inhibitors of HCV NS5B
  • Antiviral compounds inhibitors of HCV NS5B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0230] In one embodiment, compounds of general formula (I) are provided:

[0231] E. 1a -V 1a –C(=O)-P 1a -W 1a -P 1b -C(=O)-V 1b -E 1b (I)

[0232] in:

[0233] W 1a yes

[0234]

[0235] and W 1a is optionally substituted with one or more groups independently selected from halogen, alkyl, haloalkyl, optionally substituted aryl, optionally substituted heterocycle, and cyano;

[0236] Y 5 Yes-O-CH 2 -, -CH 2 -O-, -O-C(=O)- or -C(=O)-O-; X 5 is-CH 2 -CH 2 -or-CH=CH-;

[0237] E. 1a is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl), or -N(H)(cycloalkoxycarbonyl); or E 1a -V 1a together is R 9a ;

[0238] E. 1b is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl), or -N(H)(cycloalkoxycarbonyl); or E 1b -V 1b together is R 9b ;

[0239] V 1a and V 1b each independently selected from:

[0240]

[0241] P 1a selected from:

[0242]

[0243]

[0244] P 1b selected from:

[0245]

[0246] with

[0247] R 9a and R 9b each independent...

Embodiment AA

[0316]

[0317]

[0318] 3,4-Dihydronaphthalen-1(2H)-one: Dissolve 7-hydroxy-1-tetralone (13.9 g, 85.7 mmol) and 1-bromo-2- To a stirred solution of (bromomethyl)-4-chlorobenzene (25.6 g, 90.0 mmol), potassium carbonate (24 g, 172 mmol) was added. The reaction was stirred under argon for 18 hours, then diluted with ethyl acetate (1 L). The organics were washed three times with water and once with brine. The organic layer was then dried over magnesium sulfate, filtered and concentrated. To the resulting oil was added methanol (500 mL), and the suspension was stirred for thirty minutes. 7-(2-Bromo-5-chlorobenzyloxy)-(27.8 g, 89% yield) was isolated by filtration.

[0319] 3-Chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one: Add palladium(II) pivalate (1.18g, 3.8mmol), tri( In a 1L flask of 4-fluorophenyl)phosphine (1.20g, 3.8mmol), pivalic acid (2.33g, 22.8mmol) and potassium carbonate (31.8g, 228mmol), add dimethylacetamide (380mL) A solution of 7-(2-bromo-5-chlo...

Embodiment AB

[0327]

[0328]

[0329] (2S,4S)-1-tert-butyl 2,4-dimethylpyrrolidine-1,2,4-tricarboxylate. To a solution of (2S,4S)-1-tert-butyl 2-methyl 4-cyanopyrrolidine-1,2-dicarboxylate (9.0 g, 35.4 mmol) in MeOH (196 mL) was added HCl ( 4M in 1,4-dioxane, 100 mL, 403 mmol). The solution was stirred at room temperature for 16 h, and concentrated in vacuo. The crude intermediate was dissolved in ethyl acetate (180 mL) and basified with aqueous bicarbonate (sat.). Di-tert-butyl bicarbonate (8.5 g, 38.9 mmol) was added and the biphasic solution was stirred at room temperature for 12 h. The layers were then separated, and the aqueous layer was back extracted with ethyl acetate. The combined organic layers were washed with brine, passed through Na 2 SO 4 Dried and concentrated. The crude oil was purified by silica gel chromatography (15% to 40% to 100% ethyl acetate / hexanes) to provide (2S,4S)-1-tert-butyl 2,4-dimethylpyrrolidine-1,2 , 4-Tricarboxylate (9.56 g, 94%).

[0330] (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The disclosure is related to anti-viral compounds of formula (I), compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Application No. 13 / 831,116, filed March 14, 2013, and U.S. Provisional Application No. 61 / 647,966, filed May 16, 2012, both of which are incorporated by reference in their entirety In this application. Background technique [0003] Hepatitis C is considered a chronic viral disease of the liver characterized by liver disease. Although drugs that target the liver are widely used and have shown effectiveness, toxicity and other side effects limit their usefulness. Inhibitors of hepatitis C virus (HCV) are used to limit the establishment and progression of HCV infection and in diagnostic tests for HCV. [0004] There is a need for new HCV therapeutics. In particular, there is a need for HCV therapeutics that are active against a broad range of HCV genotypes (eg, genotypes 1a, 1b, 2a, 3a, 4a). There is also a particular need for agents that are less prone to viral resistance. Inhi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D491/052A61K31/4188
CPCC07D491/052A61K31/4188A61P31/12A61K45/06A61K31/7068C07D491/04A61K31/7056A61K38/21A61K31/7072A61P1/16A61P31/00A61P31/14A61P43/00A61K2300/00C07D413/14
Inventor 约翰·O.·林克杰瑞米·J.·柯特尔特里萨·亚历杭德拉·特雷霍·马丁伊丽莎白·M.·培根
Owner GILEAD SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com